Hematologic Malignancy
B Lymphoblastic Leukemia/Lymphoma
CI-CAN-00000469Explore in graph →
Hematologic164 active trials1 approved drugs180 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000469Explore in graph →
Variants & evidence
296 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ABL1 Fusion5 | ||||||||
| (oncogenic) | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Oncogenic | C | Supports Oncogenicity | 3 | accepted | EID9158The authors describe two cases of B-lymphoblastic leukemia (B-ALL) with the t(1;9)(p34;q34) rearrangement, resulting in a fusion between the pre-mRNA processing protein gene SFPQ and the ABL1 kinase g… (full text at CIViC) PMID 21388681 · Duhoux et al., 2011 · Open in CIViC | civic |
| (diagnostic) | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | C | Supports Positive | 3 | accepted | EID9160A 34-year-old woman was hospitalized because of weakness and mild fever. Physical examination revealed multiple and superficial lymph nodes. Peripheral blood counting showed a 47% blasts. Bone marrow … (full text at CIViC) PMID 27894117 · Sheng et al., 2017 · Open in CIViC | civic |
| (oncogenic) | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Oncogenic | C | Supports Oncogenicity | 2 | accepted | EID9161A 22-year-old male presenting with B-lymphoblastic leukemia (B-ALL) characterized by a t(1;9)(p34;q34) was found to carry an SFPQ-ABL1 fusion. The fusion was confirmed by amplification of the genomic … (full text at CIViC) PMID 18205209 · Hidalgo-Curtis et al., 2008 · Open in CIViC | civic |
| 〃 | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Oncogenic | C | Supports Oncogenicity | 2 | accepted | EID9362219 newly diagnosed NCI high-risk, Ph-negative, B-ALL patients between ages 1 to 18 were enrolled on DFCI ALL Consortium protocol 05-001 (NCT00400946) between 2005 and 2011. This study sought to deter… (full text at CIViC) PMID 29507076 · Tran et al., 2018 · Open in CIViC | civic |
| Dasatinib + ImatinibSequential | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID9159Using fluorescence in situ hybridization (FISH) analysis with break-apart probes, the authors screened retrospectively 55 pediatric and 50 adult B-lymphoblastic leukemia (B-ALL) cases negative for com… (full text at CIViC) PMID 32306475 · Biloglav et al., 2020 · Open in CIViC | civic |
| PDGFRB e6::e112 | ||||||||
| (oncogenic) | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Oncogenic | C | Supports Oncogenicity | 4 | submitted | EID13007A 4 yr old boy was diagnosed with precursor B-cell ALL. Patient had normal karyotype. The patient was refractory to prolonged induction therapy. Presence of PDGFRB rearrangement was indicated by F… (full text at CIViC) PMID 29434033 · Zhang et al., 2018 · Open in CIViC | civic |
| Imatinib | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Predictive | C | Supports Sensitivity Response | 4 | submitted | EID13008A 4 yr old boy with AGGF1::PDGFRB Fusion, and Ph-Like B-ALL was refractory to chemotherapy and did not respond to induction therapy. The patient was given imatinib, and within 8 weeks leukemia clearan… (full text at CIViC) PMID 29434033 · Zhang et al., 2018 · Open in CIViC | civic |
| PDGFRB Fusion + PDGFRB C843G1 | ||||||||
| CHZ868 | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID6999A 4 year old boy with normal karyotype relapsed, refractory B-cell ALL had initial but not sustained response to TKIs including imatinib, dasatinib and nilotinib, followed by a bone marrow transplant.… (full text at CIViC) PMID 29434033 · Zhang et al., 2018 · Open in CIViC | civic |
| JAK2 Fusion2 | ||||||||
| (diagnostic) | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | C | Supports Positive | 3 | accepted | EID7671In the study involving 1725 B-ALL patients, 264 were identified by microarray-based algorithm to have a Ph-like expression signature. Next generation sequencing (RNAseq, WGS, and/or WES) performed on … (full text at CIViC) PMID 25207766 · Roberts et al., 2014 · Open in CIViC | civic |
| 〃 | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | C | Supports Positive | 3 | accepted | EID8095In B-lymphoblastic leukemia/lymphoma (B-ALL), the presence of this fusion is associated with so-called BCR/ABL1 like (Ph-like) subtype of the disease. The ATF7IP-JAK2 fusion is rare; in this study inv… (full text at CIViC) PMID 27870571 · Roberts et al., 2017 · Open in CIViC | civic |
| ABL1 Fusion7 | ||||||||
| (diagnostic) | B Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1ALIAS | Diagnostic | B | Supports Positive | 4 | accepted | EID12088In this 1999 study the authors included 1322 B-lymphoblastic leukemia (B-ALL) cases in patients under the age of 21 years. Cytogenetic data showed that 30 cases (2.3%) had the t(9;22)(q34;q11) known t… (full text at CIViC) PMID 10194126 · Uckun et al., 1999 · Open in CIViC | civic |
| 〃 | B Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1ALIAS | Diagnostic | B | Supports Positive | 4 | accepted | EID12089In this 1991 study the authors included 363 children diagnosed with B-lymphoblastic leukemia (B-ALL). Cytogenetic analysis idenitified a t(9;22) (q34;q11) also known as BCR::ABL1 in 15 cases (4.1%). T… (full text at CIViC) PMID 1991160 · Fletcher et al., 1991 · Open in CIViC | civic |
| 〃 | ||||||||
| ABL1 T315I + ABL1 Fusion1 | ||||||||
| Ponatinib | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 4 | submitted | EID11236In a phase 2, open-label trial, 449 patients with either CML or Philadelphia chromosome-positive ALL or has a BCR-ABL T315I mutation were enrolled and administered once daily 45 mg ponatinib. In the 3… (full text at CIViC) PMID 24180494 · Cortes et al., 2013 · Open in CIViC | civic |
| FGFR1 Fusion1 | ||||||||
| (oncogenic) | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Oncogenic | C | Supports Oncogenicity | 2 | submitted | EID1172670 yo with t(8;22)(p11;q11) and BCR::FGFR1 rearrangement presenting as pre-B ALL with complex cytogenetic abnormalities. Flow cytometric analysis at diagnosis showed B cell immunophenotype. BCR-FGFR1 … (full text at CIViC) PMID 20594995 · Baldazzi et al., 2010 · Open in CIViC | civic |
| JAK2 Fusion4 | ||||||||
| (diagnostic) | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | C | Supports Positive | 4 | accepted | EID7698In this study which included 1389 cases of high-risk pediatric B-ALL, 284 were identified by TaqMan Low Density Array to have a Ph-like gene expression signature. RT-PCR or RNAseq performed on the 129… (full text at CIViC) PMID 28408464 · Reshmi et al., 2017 · Open in CIViC | civic |
| 〃 | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | C | Supports Positive | 4 | accepted | EID8101In this study involving 574 pediatric B-ALL patients (from a Dutch/German cohort), 77 were shown to be Ph-like cases identified by hierarchical clustering of gene expression data. In one male patient … (full text at CIViC) PMID 27894077 · Boer et al., 2017 · Open in CIViC | civic |
| 〃 | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | C | Supports | ||||
| PDGFRA Fusion2 | ||||||||
| Imatinib | B Acute Lymphoblastic LeukemiaALIAS | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID7990A 47-year-old man was diagnosed with pre-B-cell acute lymphoblastic leukemia. FISH and nested PCR revealed the patient had a t(4;22)(q12;11) translocation that created an in-frame BCR-PDGFRA fusion. T… (full text at CIViC) PMID 12944919 · Trempat et al., 2003 · Open in CIViC | civic |
| Chemotherapy + ImatinibCombination | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Predictive | C | Supports Sensitivity Response | 2 | submitted | EID12582A 39-year-old Chinese man was hospitalized in May 2021 with concerns of thirst and weight loss. Immature B lymphocytes were detected in blood (83.8%) and bone marrow (87%) and FISH showed the absence … (full text at CIViC) PMID 41143846 · Hua et al., 2024 · Open in CIViC | civic |
| BLK Expression1 | ||||||||
| Ibrutinib | B Acute Lymphoblastic LeukemiaALIAS | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID9288A preclinical study investigated BTK inhibitor ibrutinib as a potential inhibitor for patients with pre-BCR + B cell acute lymphoblastic leukemia (B-ALL). In validating the significance of BTK and BLK… (full text at CIViC) PMID 28031181 · Kim et al., 2017 · Open in CIViC | civic |
| BTK Expression1 | ||||||||
| Ibrutinib | B Acute Lymphoblastic LeukemiaALIAS | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID9287A preclinical study investigated BTK inhibitor ibrutinib as a potential inhibitor for patients with pre-BCR + B cell acute lymphoblastic leukemia (B-ALL). In validating the significance of BTK and BLK… (full text at CIViC) PMID 28031181 · Kim et al., 2017 · Open in CIViC | civic |
| CD19 delta-ex2, delta-ex5-61 | ||||||||
| Tisagenlecleucel | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Predictive | D | Supports Resistance | 4 | submitted | EID9700In an in vitro study, cells transduced with CD19 delta5-6 and CD19 delta2 show significantly no response to CART-19 therapy compared to CD19-FL transduced cells. PMID 26516065 · Sotillo et al., 2015 · Open in CIViC | civic |
| PDGFRB Fusion2 | ||||||||
| (oncogenic) | B Acute Lymphoblastic LeukemiaALIAS | Oncogenic | D | Supports Oncogenicity | 4 | submitted | EID13181A somatic out-of-frame CD74intr::PDGFRB rearrangement joined CD74 exon 1 to PDGFRB exon 11 and retained 75 bp of CD74 intronic sequence containing a premature stop codon. Rather than producing a conve… (full text at CIViC) PMID 36810896 · Sadras et al., 2023 · Open in CIViC | civic |
| Dasatinib | B Acute Lymphoblastic LeukemiaALIAS | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID13182A 22-month-old patient with high-risk Philadelphia chromosome-like B-cell acute lymphoblastic leukemia harboring CD74intr::PDGFRB had 46.3% residual bone marrow blasts at the end of induction therapy.… (full text at CIViC) PMID 36810896 · Sadras et al., 2023 · Open in CIViC | civic |
| ABL1 Fusion1 | ||||||||
| (diagnostic) | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | C | Supports Positive | 2 | accepted | EID9078This study included 1389 cases of high-risk pediatric B-ALL, of which 284 were identified by TaqMan Low Density Array to have a BCR-ABL1-like (Ph-like) gene expression signature. RT-PCR or RNAseq perf… (full text at CIViC) PMID 28408464 · Reshmi et al., 2017 · Open in CIViC | civic |
| ABL1 Fusion2 | ||||||||
| (oncogenic) | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Oncogenic | C | Supports Oncogenicity | 2 | submitted | EID13001In a 56-year-old female diagnosed with B-lymphoblastic leukemia/lymphoma (B-ALL), transcriptome sequencing (RNA-seq) identified a CNTRL::ABL1 fusion. At diagnosis, the patient had a white blood cell c… (full text at CIViC) PMID 37103615 · Tan et al., 2023 · Open in CIViC | civic |
| 〃 | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Oncogenic | C | Supports Oncogenicity | 2 | submitted | EID13002In a 15-year-old male with B-lymphoblastic leukemia/lymphoma (B-ALL), a novel CNTRL::ABL1 was identified during screening of 212 childhood B-cell acute lymphoblastic leukemia cases. Samples lacking kn… (full text at CIViC) PMID 33707599 · Hsu et al., 2021 · Open in CIViC | civic |
| CRLF2 F232C2 | ||||||||
| (prognostic) | Adult B Acute Lymphoblastic LeukemiaALIAS | Prognostic | D | Supports Poor Outcome | 4 | submitted | EID6094In vitro expression experiments of CRLF2 F232C in murine BaF3 cells and human UT7 cells show that this mutation leads to constitutive dimerization and cytokine-independent signaling. This leads to tra… (full text at CIViC) PMID 20018760 · Yoda et al., 2010 · Open in CIViC | civic |
| JAK Inhibitor I | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 4 | submitted | EID7210The CRLF2 Phe232Cys somatic mutation was identified in 3/14 adult B-ALL specimens overexpressing CRLF2. Functional studies in BaF3 cells demonstrated constitutive dimerization, and retains ability to … (full text at CIViC) PMID 20018760 · Yoda et al., 2010 · Open in CIViC | civic |
| CSF1R RCSD1::ABL21 | ||||||||
| (diagnostic) | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Diagnostic | C | Supports Positive | 3 | rejected | civic | |
| DUX4 Fusion + DUX4 Fusion1 | ||||||||
| (diagnostic) | B Acute Lymphoblastic Leukemia with DUX4 RearrangementALIAS | Diagnostic | B | Supports Positive | 4 | submitted | EID11523Integrated genomic analysis of was performed for 1,988 childhood and adult B-ALL cases. 106 cases (5.3%) showed DUX4 rearrangements, commonly with the IGH region. These cases were characterized by a u… (full text at CIViC) PMID 30643249 · Gu et al., 2019 · Open in CIViC | civic |
| JAK2 Fusion1 | ||||||||
| (diagnostic) | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | C | Supports Positive | 3 | accepted | EID7672In the study involving 1725 B-ALL patients, 264 were identified by microarray-based algorithm to have a Ph-like expression signature. Next generation sequencing (RNAseq, WGS, and/or WES) performed on … (full text at CIViC) PMID 25207766 · Roberts et al., 2014 · Open in CIViC | civic |
| PDGFRB Fusion6 | ||||||||
| (diagnostic) | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | C | Supports Positive | 3 | submitted | EID11625B-ALL cases with high-risk clinical features or suggestion of a kinase rearrangement were subjected to low density gene expression array to determine Ph-like status. 3 patients (ages 6, 14.4, and 19.… (full text at CIViC) PMID 25207766 · Roberts et al., 2014 · Open in CIViC | civic |
| Imatinib | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID1310A 10-year-old boy with B-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and harboring an EBF1-PDGFRB fusion responded to imatinib plus induction chemotherapy (vincristine, d… (full text at CIViC) PMID 23835704 · Weston et al., 2013 · Open in CIViC | civic |
| 〃 | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Predictive | C | Supports | ||||
| EPOR Overexpression1 | ||||||||
| (diagnostic) | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | A | Supports Positive | 3 | submitted | EID7023The study showed that the EPOR gene rearrangements with immunoglobulin loci are associated with Ph-like molecular subtype of B-ALL, characterized by a gene-expression profile similar to that of the BC… (full text at CIViC) PMID 25207766 · Roberts et al., 2014 · Open in CIViC | civic |
| EPOR rearrangements1 | ||||||||
| (diagnostic) | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | B | Supports Positive | 4 | accepted | EID12397This 2017 study is result of collaboration of multiple institutions and was led by St. Jude Children's Research Hospital team. The total cohort of 3115 B-ALL patients (all ages) was studied, with 212 … (full text at CIViC) PMID 26859458 · Iacobucci et al., 2016 · Open in CIViC | civic |
| ABL1 Fusion4 | ||||||||
| (diagnostic) | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | B | Supports Positive | 4 | accepted | EID9073This study determined the incidence, clinical characteristics and associated genetic abnormalities in hematologic malignancies with the ETV6-ABL1 fusion. The total of 44 new and previously published E… (full text at CIViC) PMID 27229714 · Zaliova et al., 2016 · Open in CIViC | civic |
| 〃 | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | C | Supports Positive | 2 | submitted | EID11614B-ALL cases with high-risk clinical features or suggestion of a kinase rearrangement were subjected to low density gene expression array to determine Ph-like status. 2 of 2 patients (ages 5 and 82 ye… (full text at CIViC) PMID 25207766 · Roberts et al., 2014 · Open in CIViC | civic |
| Dasatinib | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Predictive | ||||||
Data updated 21 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.
| B Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1ALIAS |
| Diagnostic |
| B |
| Supports Positive |
| 4 |
| accepted |
EID12090In this large 2022 landscape study the authors include 2,754 children, adolescents and young adults (AYA) with newly diagnosed B-ALL (n=2,288 cases) or T-ALL (n=466). Median age at diagnosis was 6.4 y… (full text at CIViC) PMID 36050548 · Brady et al., 2022 · Open in CIViC |
| civic |
| 〃 | B Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1ALIAS | Diagnostic | B | Supports Positive | 3 | accepted | EID12087In this 1986 study the authors included 329 newly diagnosed patients with B-lymphoblastic leukemia (B-ALL), including 157 children and 172 adults. Cytogenetic analysis detected a t(9;22)(q34;q11) abno… (full text at CIViC) PMID 3455828 · Bloomfield et al., 1986 · Open in CIViC | civic |
| Bosutinib | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 4 | submitted | EID11287In a phase I/II, open-label trial, 570 patients with Philadelphia chromosome–positive CML were enrolled. Patient cohorts included second-line chronic phase (CP) CML (n = 286), third-/fourth-line CP CM… (full text at CIViC) PMID 24345751 · Kantarjian et al., 2014 · Open in CIViC | civic |
| Dasatinib | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 4 | submitted | EID11235In a phase 2, open-label trial, a cohort of 78 patients with BCR-ABL positive ALL received 60 mg/m2 of dasatinib daily for up to 24 months in combination with chemotherapy (AIEOP-BFM ALL 2000 multi-ag… (full text at CIViC) | civic |
| Nilotinib | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 4 | submitted | EID11288In this phase 1 dose-escalation study, 119 patients with imatinib-resistant, Ph-positive CML or acute lymphoblastic leukemia (ALL) to receive nilotinib orally at doses of 50 mg, 100 mg, 200 mg, 400 mg… (full text at CIViC) PMID 16775235 · Kantarjian et al., 2006 · Open in CIViC | civic |
| 3 |
| accepted |
EID7697In the study involving 1725 B-ALL patients, 264 were identified by microarray-based algorithm to have a Ph-like expression signature. Next generation sequencing (RNAseq, WGS, and/or WES) performed on … (full text at CIViC) PMID 25207766 · Roberts et al., 2014 · Open in CIViC |
| civic |
| 〃 | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | C | Supports Positive | 3 | accepted | EID8096In B-lymphoblastic leukemia/lymphoma (B-ALL), the presence of this fusion is associated with so-called BCR/ABL1 like (Ph-like) subtype of the disease. In this study involving 798 B-ALL patients of whi… (full text at CIViC) PMID 27870571 · Roberts et al., 2017 · Open in CIViC | civic |
| 2 |
| submitted |
EID7127EBF1-PDGFRB fusion was detected in leukemia cells of a 6 year old male who presented with B-ALL and an initial WBC of 244,400. He received 4-drug induction chemotherapy but failed to enter remission w… (full text at CIViC) PMID 25207766 · Roberts et al., 2014 · Open in CIViC |
| civic |
| 〃 | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID12644In a group of 73 of Dutch and German children with Ph-Like B Cell Precursor ALL, 12 tyrosine kinase-activating fusion genes were found. 4 of the Fusions were EBF1::PDGFRB. Leukemic cells taken from t… (full text at CIViC) | civic |
| Chemotherapy + ImatinibCombination | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID8260A 9 year old girl with B-lymphoblastic leukemia/ lymphoma (2016 WHO) relapsed 15 months post-maintenance chemotherapy. FISH and genomic analysis detected the EBF1-PDGFRB fusion (exon 11 with Exon14). … (full text at CIViC) PMID 32068648 · Sakurai et al., 2021 · Open in CIViC | civic |
| Dasatinib + ImatinibSubstitutes | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID7128The EBF1-PDGFRB fusion was detected in leukemia cells of a 7 year old Latino boy who presented with B-ALL and initial WBC of 600,000. He failed to enter remission with 4 drug induction (90% blasts at … (full text at CIViC) PMID 25207766 · Roberts et al., 2014 · Open in CIViC | civic |
| C |
| Supports Sensitivity Response |
| 2 |
| accepted |
EID6969An adult patient (82 yo) who presented with B-ALL (initial WBC of 183,000) with ETV6-ABL1 fusion was treated with dasatinib as a single agent after his chemotherapy had to be stopped due to toxicity. … (full text at CIViC) PMID 25207766 · Roberts et al., 2014 · Open in CIViC |
| civic |
| Imatinib | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID9171A 4-year-old female presented with relapsed B-cell precursor ALL and no MLL or BCR-ABL1 rearrangement per cytogenetic studies. During multiple periods of short remission and relapse she was treated wi… (full text at CIViC) PMID 30028819 · Mankuzhy et al., 2019 · Open in CIViC | civic |